Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
When would you offer nivolumab/relatlimab to a metastatic melanoma patient following progression on BRAF/MEK targeted therapy?
Related Questions
How would you treat locally advanced melanoma of the scalp with several in transit lesions and a metastatic lesion to the parotid if the patient is progressing on immunotherapy such as pembrolizumab?
How would you approach management of a large, fungating squamous cell carcinoma of the auricle if surgical management is not desired by the patient?
How would you manage a patient who developed stage III melanoma while receiving cemiplimab (cycle 10) for locally advanced cutaneous squamous cell carcinoma?
How would a low tumor mutational burden (<10) influence your decision to offer neoadjuvant immunotherapy for cutaneous squamous cell carcinoma?
What is the optimal approach to managing oral toxicities, such as dysgeusia, caused by immune checkpoint inhibitors (ICIs)?
How would you sequence lifileucel (TIL therapy) in a patient with metastatic melanoma who is BRAF wild-type (BRAF WT) and progressed on adjuvant Nivolumab?
What is the current role of ctDNA in guiding the selection of adjuvant treatment for stage II-IIIA melanoma?
In what situations would you recommend adjuvant radiation therapy for patients with locally advanced and/or recurrent basal cell carcinoma that receive vismodegib followed by surgery?
How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?
How do you manage new-onset vitiligo in a patient on immune checkpoint inhibitors?
